Interferon antagonists encoded by SARS-CoV-2 at a glance

被引:20
|
作者
Lee, Jung-Hyun [1 ,2 ]
Koepke, Lennart [1 ]
Kirchhoff, Frank [1 ]
Sparrer, Konstantin M. J. [1 ]
机构
[1] Ulm Univ, Med Ctr, Inst Mol Virol, Meyerhofstr 1, D-89081 Ulm, Germany
[2] Univ Seoul, Dept Life Sci, Seoul 02504, South Korea
关键词
Interferon; SARS-CoV-2; Innate immunity; COVID-19; Immune evasion; PAPAIN-LIKE PROTEASE; RIG-I;
D O I
10.1007/s00430-022-00734-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The innate immune system is a powerful barrier against invading pathogens. Interferons (IFNs) are a major part of the cytokine-mediated anti-viral innate immune response. After recognition of a pathogen by immune sensors, signaling cascades are activated that culminate in the release of IFNs. These activate cells in an autocrine or paracrine fashion eventually setting cells in an anti-viral state via upregulation of hundreds of interferon-stimulated genes (ISGs). To evade the anti-viral effect of the IFN system, successful viruses like the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolved strategies to counteract both IFN induction and signaling. In fact, more than half of the about 30 proteins encoded by SARS-CoV-2 target the IFN system at multiple levels to escape IFN-mediated restriction. Here, we review recent insights into the molecular mechanisms used by SARS-CoV-2 proteins to suppress IFN production and the establishment of an anti-viral state.
引用
收藏
页码:125 / 131
页数:7
相关论文
共 50 条
  • [1] Interferon antagonists encoded by SARS-CoV-2 at a glance
    Jung-Hyun Lee
    Lennart Koepke
    Frank Kirchhoff
    Konstantin M. J. Sparrer
    Medical Microbiology and Immunology, 2023, 212 : 125 - 131
  • [2] Immune evasion of SARS-CoV-2 from interferon antiviral system
    Min, Yuan-Qin
    Huang, Mengzhuo
    Sun, Xiulian
    Deng, Fei
    Wang, Hualin
    Ning, Yun-Jia
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2021, 19 : 4217 - 4225
  • [3] Interferon Treatments for SARS-CoV-2: Challenges and Opportunities
    Jhuti, Diya
    Rawat, Angeli
    Guo, Christina M.
    Wilson, Lindsay A.
    Mills, Edward J.
    Forrest, Jamie, I
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (03) : 953 - 972
  • [4] Interferon Treatments for SARS-CoV-2: Challenges and Opportunities
    Diya Jhuti
    Angeli Rawat
    Christina M. Guo
    Lindsay A. Wilson
    Edward J. Mills
    Jamie I. Forrest
    Infectious Diseases and Therapy, 2022, 11 : 953 - 972
  • [5] Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options
    Znaidia, Mariem
    Demeret, Caroline
    van der Werf, Sylvie
    Komarova, Anastassia V.
    VIRUSES-BASEL, 2022, 14 (06):
  • [6] Interferon resistance of emerging SARS-CoV-2 variants
    Guo, Kejun
    Barrett, Bradley S.
    Morrison, James H.
    Mickens, Kaylee L.
    Vladar, Eszter K.
    Hasenkrug, Kim J.
    Poeschla, Eric M.
    Santiago, Mario L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (32)
  • [7] Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
    Lokugamage, Kumari G.
    Hage, Adam
    de Vries, Maren
    Valero-Jimenez, Ana M.
    Schindewolf, Craig
    Dittmann, Meike
    Rajsbaum, Ricardo
    Menachery, Vineet D.
    JOURNAL OF VIROLOGY, 2020, 94 (23)
  • [8] SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination
    Manfrini, Nicola
    Notarbartolo, Samuele
    Grifantini, Renata
    Pesce, Elisa
    ANTIBODIES, 2024, 13 (01)
  • [9] Interferon-stimulated genes and their antiviral activity against SARS-CoV-2
    Maria Ortega-Prieto, Ana
    Jimenez-Guardeno, Jose M.
    MBIO, 2024, 15 (09): : e0210024
  • [10] Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection
    Chiale, Carolina
    Greene, Trever T.
    Zuniga, Elina, I
    IMMUNOLOGICAL REVIEWS, 2022, 309 (01) : 12 - 24